One Biosciences launches the LARYCARE clinical study, its second discovery program

PARIS–(BUSINESS WIRE)–One Biosciences, a biotechnology company co-founded by Dr. Céline Vallot, Institut Curie and Home Biosciences, combining the power of AI and single-cell technologies to discover new therapeutic targets and develop new precision drugs, announced today that it has initiated the LARYCARE prospective clinical study for single-cell profiling of carcinoma of the larynx and hypopharynx.

This new study aims to better understand, with an unprecedented granularity of information, the mechanisms involved in the response and resistance to neoadjuvant chemotherapy. The objective is to identify new predictive biomarkers of the response to neoadjuvant treatment in advanced carcinomas of the larynx and hypopharynx as well as to discover new potential targeted therapies. One Biosciences will evaluate samples from patients enrolled at Clinique Hartmann and Hôpital Paris Saint-Joseph, in partnership with the Rafaël Institute Research Center (Institut Rafaël Center de Recherche).

This clinical study follows a first program launched in May 2021 in collaboration with the Institut Curie in patients with high-grade serous ovarian cancer, aimed at identifying new precision drugs, by evaluating samples from the Institute’s SCANDARE trial.

One Biosciences has completed a financing of seven million euros initiated at its creation in July 2020 with Home Biosciencesan asset-centric biotechnology company, itself backed by a US company Redmile Group and based in France Sofinnova Partners, two leading VCs in the field of biotechnology. One Biosciences also benefited from Support from BPI France through non-dilutive grants (BFTE, PIA and DeepTech Development Assistance).

Doctor Celine Vallot, co-founder and chairman of the scientific advisory board of One Biosciencessaid: “Single-cell analysis of tumor tissue during treatment now allows researchers to access an unprecedented level of understanding of the cellular mechanisms at work in cancer patients. Using unique molecular technologies and algorithms for proprietary artificial intelligence, One Biosciences maps tumors with unparalleled resolution to shed light on new biological markers, enabling the anticipation of each patient’s response to chemotherapy. Our technology platform also paves the way for the development of ultra-targeted therapies against cancers and complex diseases that are difficult to treat.

dr. Magali Richard, co-founder of Home Biosciences and CEO of One Biosciencessaid “We have assembled a unique discovery engine in record time. We are now continuing our aggressive growth trajectory with two programs already underway and two new projects to launch soon in high unmet medical needs. We are in line with our sheet initial road and reaffirm our ambition to make One Biosciences a leader in the development of therapies powered by AI and single cells.”

One Biosciences relies on a strong multidisciplinary Scientific Council, chaired by Dr Céline Vallot, co-founder of One Biosciences, who received the prestigious CNRS Innovation Medal on June 16, 2022. A Biosciences SAB is composed of Alexandre Gramfort, PhD Director of research in artificial intelligence at Inria, Sophie Postel-Vinay, MD/PhD, Senior Medical Oncologist – Research Clinician, Drug Development Department (DITEP), ATIP U981 INSERM Team Leader at the Cancer Campus of Gustave Roussy and Julien Zuber, MD/PhD, Transplant nephrologist at Necker Hospital and professor of clinical immunology at Paris Descartes University.

About the Hartmann Clinic:

About Paris Saint Joseph Hospital:

About the Rafaël Institute and the Rafaël Institute Research Center:

About Institut Curie:


About Home Biosciences:

About One Biosciences:

About Armand Downs

Check Also

Week in Review: Insilico Signs Six AI-Drug Discovery Deal with Sanofi Worth Up to $1.2 Billion

jittawit.21 Offers and financing Insilico Medicine, a Hong Kong and New York-based AI drug discovery …